Gynecologic Oncology Practice Questions

Q: A 35-year-old G3P3 with a Pap smear showing high-grade squamous intraepithelial lesion of the cervix (CIN III) has an inadequate colposcopy. Cone biopsy shows squamous cell cancer that has invaded only 1 mm beyond the basement membrane. There are no confluent tongues of tumor, and there is no evidence of lymphatic or vascular invasion. The margins of the cone biopsy specimen are free of disease. What is your diagnosis?

Microinvasive cancer. **Explanation:** The diagnosis is **Microinvasive Squamous Cell Carcinoma (Stage IA1)**. According to the FIGO staging for cervical cancer, Stage IA1 is defined as invasive carcinoma that can be identified only by microscopy, with a maximum depth of invasion **≤ 3 mm**. In this case, the tumor invades only **1 mm** beyond the basement membrane, and the absence of lymphovascular space invasion (LVSI) and clear margins on the cone biopsy confirm this diagnosis. Microinvasive cancer represents a transition point where the malignant cells have breached the basement membrane but have a very low risk of pelvic lymph node metastasis (<1%). **Analysis of Incorrect Options:** * **Option A (Carcinoma of low malignant potential):** This term is typically used for borderline ovarian tumors, not cervical pathology. * **Option C (ASC-US):** This is a cytological category from a Pap smear indicating cells that do not look normal but do not meet the criteria for a definitive lesion. It is a precursor finding, not a histological diagnosis of invasion. * **Option D (Carcinoma in situ):** Also known as CIN III, this refers to full-thickness dysplasia where the basement membrane is **intact**. Once the basement membrane is breached (as the 1 mm invasion indicates here), it is no longer "in situ" but "invasive." **Clinical Pearls for NEET-PG:** * **FIGO Stage IA1:** Invasion ≤ 3 mm depth. Treatment of choice is **Extra-fascial Hysterectomy** (Type A). If the patient desires fertility, a **Cold Knife Conization** with clear margins is sufficient. * **FIGO Stage IA2:** Invasion > 3 mm to ≤ 5 mm. Requires Modified Radical Hysterectomy (Type B) with pelvic lymphadenectomy. * The most important prognostic factor in early-stage cervical cancer is **lymphovascular space invasion (LVSI)**.

Q: Regarding vaccination for carcinoma cervix, all of the following statements are true EXCEPT:

Does not require further examinations. **Explanation:** The correct answer is **A (Does not require further examinations)** because HPV vaccination does not eliminate the need for cervical cancer screening. **1. Why Option A is the correct (False) statement:** HPV vaccines (Bivalent, Quadrivalent, or Nonavalent) protect against the most common high-risk strains (HPV 16 and 18), which cause approximately 70% of cervical cancers. However, they do not cover all oncogenic HPV types. Therefore, vaccinated women must still undergo routine **Pap smears or HPV DNA testing** according to standard guidelines to detect lesions caused by non-vaccine strains. **2. Analysis of other options:** * **Option B:** HPV vaccines are inactivated (recombinant) vaccines. They can be safely co-administered with other vaccines (live or inactivated), such as Hepatitis B or Tdap, provided they are given at different anatomical sites. * **Option C:** While both are highly effective, some studies suggest the **Bivalent vaccine (Cervarix)** may produce higher antibody titers and offer better cross-protection against non-vaccine types (like HPV 31 and 45) compared to the **Quadrivalent vaccine (Gardasil)**, though the clinical significance of this in preventing cancer is debated. * **Option D:** The standard three-dose schedule for individuals aged 15 and older is **0, 2, and 6 months** (for Gardasil) or 0, 1, and 6 months (for Cervarix), administered intramuscularly in the deltoid. **High-Yield Clinical Pearls for NEET-PG:** * **Target Age:** Best given before the first sexual encounter (9–14 years). * **Two-dose Schedule:** For children aged 9–14 years, only two doses are required (0 and 6 months). * **Catch-up Vaccination:** Recommended up to age 26; can be considered up to age 45 based on shared clinical decision-making. * **Contraindication:** Pregnancy (though it is not an indication for termination if accidentally administered). Safe during breastfeeding.

Q: What is the most common histology of carcinoma of the endometrium?

Adenocarcinoma. **Explanation:** **Endometrial carcinoma** is the most common gynecological malignancy in developed countries and the second most common in India (after cervical cancer). **Why Adenocarcinoma is correct:** The endometrium is a mucosal lining composed of glandular epithelium. Therefore, malignancies arising from this tissue are predominantly **adenocarcinomas**. Specifically, the **Endometrioid** subtype of adenocarcinoma accounts for approximately **75-80%** of all cases. It is typically "Type I" endometrial cancer, which is estrogen-dependent and often preceded by endometrial hyperplasia. **Why other options are incorrect:** * **Squamous cell carcinoma:** This is extremely rare as a primary endometrial cancer. Squamous cells are not native to the endometrium; they usually occur due to squamous metaplasia or extension from the cervix. * **Clear cell carcinoma:** This is a "Type II" endometrial cancer. It is highly aggressive and carries a poor prognosis, but it accounts for only about **1-5%** of cases. * **Anaplastic carcinoma:** This represents an undifferentiated, rare, and highly malignant form of the disease, occurring in a very small percentage of patients. **High-Yield Clinical Pearls for NEET-PG:** * **Most common subtype:** Endometrioid Adenocarcinoma. * **Most common symptom:** Postmenopausal bleeding (PMB). * **Risk Factors:** Obesity (most significant), nulliparity, early menarche, late menopause, and Tamoxifen use. * **Protective Factors:** Combined Oral Contraceptive Pills (COCPs) and smoking (though smoking increases other risks, it lowers estrogen levels). * **Investigation of choice:** Fractional Curettage or Pipelle biopsy (Gold standard for diagnosis). * **Staging:** Endometrial cancer is **Surgically Staged** (FIGO staging).

Q: The most malignant endometrial carcinoma is:

Clear cell carcinoma. ### Explanation Endometrial carcinomas are broadly classified into two types (Bokhman’s classification). **Type II carcinomas** are non-estrogen dependent, occur in older postmenopausal women, arise from atrophic endometrium, and carry a significantly worse prognosis due to high-grade features and early lymphovascular invasion. **Why Clear Cell Carcinoma is the correct answer:** Clear cell carcinoma is a classic **Type II endometrial cancer**. It is highly aggressive, characterized by high nuclear grade, and often presents at an advanced stage. It has a high propensity for deep myometrial invasion and peritoneal spread, making it the most malignant among the options provided. **Analysis of Incorrect Options:** * **A. Adenocarcinoma (Endometrioid):** This is the most common type (Type I). It is estrogen-dependent, arises from endometrial hyperplasia, and generally has a favorable prognosis as it is often well-differentiated and diagnosed early. * **B. Adenoacanthoma:** This is a variant of endometrioid adenocarcinoma with benign squamous metaplasia. It generally carries a good prognosis, similar to typical Grade 1 adenocarcinoma. * **C. Mixed Adenosquamous Carcinoma:** This contains both malignant glandular and malignant squamous components. While it is more aggressive than simple adenocarcinoma, its prognosis is generally better than clear cell or papillary serous carcinomas. **NEET-PG High-Yield Pearls:** * **Most common type:** Endometrioid adenocarcinoma. * **Most aggressive/malignant overall:** Uterine Papillary Serous Carcinoma (UPSC) and Clear Cell Carcinoma. * **Genetic Association:** Type I is associated with PTEN mutations; Type II (Clear cell/Serous) is associated with **p53 mutations**. * **Psammoma bodies:** Frequently seen in Papillary Serous Carcinoma, not typically in clear cell. * **Clear Cell Histology:** Characterized by "hobnail" cells and glycogen-rich clear cytoplasm.

Q: Which of the following is NOT true regarding gestational trophoblastic neoplasia?

13HCG is highly elevated in both forms of molar pregnancy. **Explanation:** **1. Why Option A is the Correct Answer (The False Statement):** While hCG levels are elevated in both types of molar pregnancies, they are **markedly higher** (often >100,000 mIU/mL) primarily in **Complete Hydatidiform Moles (CHM)**. In **Partial (Incomplete) Moles (PHM)**, hCG levels are often only slightly elevated or even within the normal range for gestational age. Therefore, saying hCG is "highly elevated in both" is clinically inaccurate. **2. Analysis of Other Options:** * **Option B:** Classical symptoms (hyperemesis gravidarum, pre-eclampsia in the first trimester, and hyperthyroidism) are caused by excessively high hCG levels. Since these levels are characteristic of CHM, these symptoms are rarely seen in PHM. * **Option C:** The majority (approx. 90%) of complete moles have a **46,XX** karyotype, resulting from an "empty" egg fertilized by a single sperm that duplicates its DNA (androgenetic monospermy). * **Option D:** Partial moles are triploid, most commonly **69,XXY** (approx. 70%), resulting from the fertilization of a normal ovum by two sperm (dispermy). **Clinical Pearls for NEET-PG:** * **Snowstorm Appearance:** Classic ultrasound finding for Complete Mole. * **Fetal Parts:** Present in Partial Moles; absent in Complete Moles. * **p57 Expression:** Negative (absent) in Complete Moles (due to lack of maternal genome); Positive in Partial Moles. * **Theca Lutein Cysts:** Common in CHM due to high hCG; rare in PHM. * **Malignant Transformation:** Risk is higher in Complete Moles (15-20%) compared to Partial Moles (<5%).

Q: What is the most common site of origin for squamous cell carcinoma of the cervix?

Squamocolumnar junction. **Explanation:** The **Squamocolumnar Junction (SCJ)** is the most common site of origin for cervical squamous cell carcinoma because it contains the **Transformation Zone (TZ)**. This is a dynamic area where the columnar epithelium of the endocervix is constantly undergoing **squamous metaplasia** to become stratified squamous epithelium. These rapidly dividing, undifferentiated cells are highly susceptible to integration by high-risk Human Papillomavirus (HPV) types (16 and 18), leading to dysplasia and eventual malignancy. **Analysis of Options:** * **A. Endocervix:** This is primarily lined by simple columnar epithelium. While it is the site of origin for *adenocarcinomas*, it is not the primary site for squamous cell carcinomas. * **B. Ectocervix:** This is lined by mature stratified squamous epithelium. While cancer can spread here, the initial neoplastic transformation rarely begins in these mature, stable cells. * **D. None of the above:** Incorrect, as the SCJ is the well-established anatomical landmark for cervical oncogenesis. **High-Yield Clinical Pearls for NEET-PG:** * **Transformation Zone:** This is the area between the original SCJ and the new SCJ. It is the specific target for Pap smear sampling and colposcopic evaluation. * **Age-related shift:** The SCJ moves inward (cephalad) with age. In postmenopausal women, the SCJ is often located within the endocervical canal, making clinical visualization difficult. * **Most common type:** Squamous cell carcinoma accounts for approximately 75-80% of all cervical cancers. * **Screening:** The goal of a Pap smear is to sample cells specifically from the transformation zone to detect early dysplastic changes (CIN).

Question 1

A 35-year-old G3P3 with a Pap smear showing high-grade squamous intraepithelial lesion of the cervix (CIN III) has an inadequate colposcopy. Cone biopsy shows squamous cell cancer that has invaded only 1 mm beyond the basement membrane. There are no confluent tongues of tumor, and there is no evidence of lymphatic or vascular invasion. The margins of the cone biopsy specimen are free of disease. What is your diagnosis?

Accepted Answer

Microinvasive cancer

Answer

Carcinoma of low malignant potential

Answer

Atypical squamous cells of undetermined significance

Answer

Carcinoma in situ

Question 2

Endocervical curettage shows malignant cells in a 40-year-old lady. What is the next line of management?

Accepted Answer

Cone biopsy

Answer

Pap smear

Answer

Colposcopy

Answer

Repeat procedure and if positive, hysterectomy

Question 3

Regarding vaccination for carcinoma cervix, all of the following statements are true EXCEPT:

Accepted Answer

Does not require further examinations

Answer

Can be taken with other live vaccines at a different site

Answer

Bivalent vaccine is more efficient than Quadrivalent

Answer

Administered intramuscularly at 0, 2, and 6 months

Question 4

What is the best method for screening for cancer of the cervix?

Accepted Answer

Pap smear

Answer

Colposcopy

Answer

Biopsy

Answer

Colpomicroscopy

Question 5

What is the most common histology of carcinoma of the endometrium?

Accepted Answer

Adenocarcinoma

Answer

Squamous cell

Answer

Clear cell

Answer

Anaplastic carcinoma

Question 6

The most malignant endometrial carcinoma is:

Accepted Answer

Clear cell carcinoma

Answer

Adenocarcinoma

Answer

Adenoacanthoma

Answer

Mixed adenosquamous carcinoma

Question 7

What is the appropriate treatment for a 23-year-old mother with carcinoma in situ of the cervix?

Accepted Answer

Cone biopsy and follow-up

Answer

Total hysterectomy

Answer

Radiation

Answer

Wertheim's hysterectomy

Question 8

All are true about gestational trophoblastic disease except?

Accepted Answer

Complete mole genome is diploid

Answer

Choriocarcinoma rarely follows full-term pregnancy

Answer

Suction and curettage remove most of a hydatidiform mole

Answer

Snowstorm appearance on USG is characteristic of a hydatidiform mole

Question 9

Which of the following is NOT true regarding gestational trophoblastic neoplasia?

Accepted Answer

13HCG is highly elevated in both forms of molar pregnancy

Answer

Classical symptoms are only seen with complete moles

Answer

The genotype is 46XX in the majority of complete moles

Answer

The genotype is 69XXY in the majority of incomplete moles

Question 10

What is the most common site of origin for squamous cell carcinoma of the cervix?

Accepted Answer

Squamocolumnar junction

Answer

Endocervix

Answer

Ectocervix

Answer

None of the above

Gynecologic Oncology — MCQs

Gynecologic Oncology — MCQs

On this page

Practice by Chapter

Want unlimited practice?